Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical industry [1] Core Insights - The overall holding ratio of the pharmaceutical sector by funds has been continuously declining, with non-pharmaceutical active funds underweighting pharmaceuticals again since the first half of 2022 [9][11] - The holding ratio of all public funds in the pharmaceutical sector for the second half of 2024 is 9.6%, a decrease of 1.2 percentage points from the previous period [3][11] - The holding ratio of all active public funds in the pharmaceutical sector is 9.9%, also down by 1.2 percentage points [3][11] - Non-pharmaceutical funds have a holding ratio of 6.0%, down by 0.8 percentage points, with an increased underweight ratio of 0.26% [3][11] Fund Holdings Overview - The holding ratios for different segments within the pharmaceutical industry show varied trends, with Pharma and Bio-Tech seeing increases, while generic drugs and traditional Chinese medicine are declining [5][15] - The top three segments with increased holdings among all public funds are CXO (+3.8%), Pharma (+2.7%), and Biotech (+0.8%) [8][11] - The top three segments with decreased holdings are medical devices (-1.9%), traditional Chinese medicine (-1.9%), and blood products (-1.3%) [8][11] Detailed Fund Type Analysis - Active pharmaceutical funds are overweight in Pharma, Biotech, and CXO, while non-pharmaceutical funds are overweight in Pharma, CXO, and medical devices [8][11] - The total market value of holdings for all public funds in the pharmaceutical sector is led by 恒瑞医药 (CNY 47.7 billion), 迈瑞医疗 (CNY 45.9 billion), and 药明康德 (CNY 37.2 billion) [8][11] - The top five stocks with increased holdings include 药明康德 (+CNY 7.5 billion) and 联影医疗 (+CNY 3.7 billion) [8][11]

Group 1 - The Chinese government has filed a lawsuit against the U.S. in the WTO regarding the imposition of "reciprocal tariffs," claiming it violates WTO rules and undermines the multilateral trade system [2] - The Chinese government has added 11 U.S. companies to the "unreliable entity list" due to their military technology cooperation with Taiwan, which is seen as a threat to China's national security [3] - A total of 16 U.S. entities have been placed on an export control list to protect national security and fulfill international obligations, prohibiting the export of dual-use items to these entities [4] Group 2 - The Chinese government has implemented export controls on seven categories of medium and heavy rare earth materials, citing the need to safeguard national security and fulfill international obligations [5][6] - The Ministry of Commerce has initiated an industry competitiveness investigation into imported medical CT tubes, responding to domestic industry requests due to the adverse impact of imports on local production [7]

Financial Data and Key Metrics Changes - The company is unable to provide detailed financial results due to the deconsolidation of Invizyne's financial statements, which has delayed the filing of the 10-K report [6][14][25] - As of December 31, the combination of cash and securities was $28 million, and Big Idea investments, represented by eXoZymes, was $64 million, totaling approximately $93 million [58] - The stock price as of December 31 was $6.30, with approximately 9.9 million shares outstanding, resulting in a market value of $62 million, indicating a negative market value of $30 million [58][59] Business Line Data and Key Metrics Changes - The company has successfully launched eXoZymes, marking a significant achievement despite challenging market conditions for small IPOs [14][15] - The shareholder count has increased by 12%, reaching approximately 1,800 shareholders [15] - The onboarding of investors through MDB Direct has begun, with over 500 accounts established by the end of the year [16] Market Data and Key Metrics Changes - There is a growing demand for microcap financing, with investors seeking liquid alternatives, positioning the company as a top curator of public venture opportunities [32] - The traditional venture capital and private equity markets are facing challenges, leading to increased interest from companies looking to go public [30][31] Company Strategy and Development Direction - The primary strategic priority is to expand the investor community, focusing on partnerships with RIAs and angel groups [35][41] - The company aims to transition from episodic deal-making to creating a consistent public venture asset class portfolio [34] - The company is optimistic about presenting new Big Idea investment opportunities in the near future, with a focus on companies that are more developed and potentially have revenue [80] Management's Comments on Operating Environment and Future Outlook - Management is excited about the significant increase in opportunities being presented, both from community members and through their own curation efforts [26][27] - The regulatory environment is perceived as improving, which may facilitate new offerings, although there are concerns regarding the FDA's approval timelines [87][88] - The company is focused on maintaining operational efficiencies and reducing cash operational expenses while increasing revenue from various lines [62] Other Important Information - The company has licensed new assets from Mayo Clinic and is developing that opportunity, with plans for potential further investment [49][50] - The company continues to work with HeartBeam, which is developing groundbreaking technology for self-administered ECGs, with significant market potential [44] Q&A Session Summary Question: Does Lou Basenese still work for the organization? - Lou Basenese has left the company but remains a friend and supporter, focusing on his media presence [65][66] Question: What does the deconsolidation mean for MDB stockholders and eXoZymes' investors? - The deconsolidation will clarify the financials of MDB, separating its performance from eXoZymes, making it easier to understand [70][71] Question: How many Big Idea companies are expected to be established in 2025? - The company anticipates presenting three to four new Big Ideas this year, with some being more developed and potentially having revenue [80][81] Question: How do you see the regulatory winds changing? - The regulatory environment is perceived as improving, which may facilitate new offerings, although there are concerns regarding the FDA's approval timelines [87][88] Question: When do you expect to make any type of dividend? - The company aims to see a value-creating event within eXoZymes before considering any distributions to shareholders [92][93] Question: How should shareholders think about the investment in cash and resources relative to value creation? - The company intends to maintain a modest amount of cash for new opportunities while leveraging existing investments to create value [99][100]

文/梧桐晓编 2025年1-3月，沪、深、北三个交易所共受理IPO申报企业只有8家，其中上交所2家，都是科创板，深交所受理1家，申报主板，北交所受理5家。其中申报科创板 IPO的昂瑞微电子报告期累计亏损8.8亿元。申报深交所主板上市的华润新能源为一家设立于中国香港红筹企业，2023年扣非净利润高达82亿元。北交所受理的5 家公司选择的具体上市标准均为《上市规则》第 2.1.3 条第一项：预计市值不低于 2 亿元，最近两年净利润均不低于 1500 万元且加权平均净资产收益率平均不低 于 8%，或者最近一年净利润不低于 2500 万元且加权平均净资产收益率不低于 8%。 8家今年一季度受理的IPO申报企业基本信息 单位：亿元 | 公司简称 | 甲报板块 | 王营业务 | 最近一年 | 最近一年 | 保荐机构 | | --- | --- | --- | --- | --- | --- | | | | | 营收 | 净利润 | | | 昂瑞微电子 | 科创板 | 射频前端芯片、射频SoC芯片及其他模拟芯片的研发设计 | 21.01 | -1.1003 | 中信建投 | | | | 与销售 | | | | | 傲拓科技 ...

Core Viewpoint - The China Securities Index for the medical industry has shown a slight decline over the past month, quarter, and year-to-date, indicating a stable but slightly negative trend in the sector [2]. Group 1: Index Performance - The China Securities Index for the medical industry is currently at 566.67 points [1]. - Over the past month, the index has decreased by 0.49%, while it has seen a minimal decline of 0.02% over the past three months and year-to-date [2]. Group 2: Index Composition - The top ten weighted companies in the index include: - Mindray Medical (14.12%) - Aier Eye Hospital (8.91%) - United Imaging Healthcare (7.39%) - Aimeike (3.93%) - Huatai Medical (3.48%) - New Industries (3.41%) - Yuyue Medical (3.12%) - Shanghai Pharmaceuticals (3.04%) - Meinian Onehealth (2.57%) - Jiuan Medical (2.39%) [2]. - The index's holdings are primarily listed on the Shenzhen Stock Exchange (57.38%) and the Shanghai Stock Exchange (42.62%) [2]. Group 3: Sector Allocation - The sector allocation within the index is as follows: - Medical Devices: 34.29% - Medical Consumables: 23.16% - Pharmaceutical Commerce: 15.33% - Medical Services: 14.26% - In Vitro Diagnostics: 12.95% [2]. Group 4: Index Adjustment Mechanism - The index samples are adjusted biannually, with adjustments occurring on the next trading day following the second Friday of June and December [3]. - Weight factors are generally fixed until the next scheduled adjustment, with temporary adjustments made in response to significant events affecting sample companies [3].

Group 1: Major Achievements in Science and Technology - China has made significant advancements in space science, including the detection of gamma-ray bursts from 25.6 billion light-years away and the first measurement of black hole X-ray binary spin and orbital inclination [3][5] - Tsinghua University has developed a brain-like complementary visual perception chip, "Tianmou Chip," which reduces bandwidth by 90% and achieves 10,000 frames per second with high precision and dynamic range [3][5] - Peking University has introduced a new paradigm for crystal preparation, enhancing the purity of materials like graphite and molybdenum disulfide by 10 to 100 times [3][5] - Huayi Quantum has created the world's first commercial prototype of a quantum computing system with over 100 ion qubits, significantly enhancing quantum computing capabilities [3][5] Group 2: Economic Applications - Blue Arrow Aerospace has successfully developed the Zhuque-2 improved liquid oxygen-methane rocket, becoming the first and only liquid oxygen-methane rocket to achieve three consecutive successful launches [5][6] - Beijing University of Posts and Telecommunications has established the world's first space-ground computing test platform, enhancing AI collaboration in satellite operations [6][7] - A collaborative effort has resulted in the development of a 6G prototype system capable of 6.6 Gbps transmission speed and sub-meter level perception accuracy [7][8] - Beiqi Foton has launched a zero-carbon liquid hydrogen heavy truck with a range exceeding 1,000 km, integrating 23 innovative technologies [8][9] Group 3: National Strategic Needs - Tsinghua University has developed a mobile hybrid processing robot that significantly improves processing precision and efficiency for large complex components used in major national projects [10][11] - State Grid Corporation has created a flexible DC converter for offshore wind power, increasing power density by 37% and reducing overall project costs by 15% [11][12] - China National Offshore Oil Corporation has successfully conducted the world's first joint extraction of natural gas hydrates and shallow gas, achieving a daily gas production rate exceeding 100,000 cubic meters [12][13] - A new large-scale high-temperature superconducting coating device has been developed, supporting the domestic production of superconducting electronic devices [13][14] Group 4: Health and Well-being - The "Beijing Brain No. 1" intelligent brain-machine interface system has been developed, achieving over 98% effective channel count for patients with motor function disorders [15][16] - A new covalent technology for radioactive drugs has been developed, increasing tumor delivery efficiency by over 10 times while minimizing side effects [16][17] - A domestic first integrated surgical robot for brain and spine procedures has been created, achieving a positioning accuracy of ≤0.5 mm [17][18] - The first targeted drug for brain glioma, "Bertinib," has been developed, significantly extending patient survival and reducing disease progression risk [18][19] - The ARC biological coupling technology has been introduced, enhancing nitrogen-fixing efficiency and crop yield while controlling mycotoxin production [19][20]

Investment Rating - The investment rating for the company is "Buy" [4][18]. Core Views - The company has released a stock incentive plan for 2025, aiming to solidify growth certainty with a target of 20% year-on-year growth for 2026 [3]. - The U.S. ventilator market is gradually stabilizing, with a projected recovery in 2025, leading to potential high growth for the company [4]. - The domestic business share is steadily increasing, and there is potential for market share growth overseas, particularly in the U.S. and Europe [4]. Summary by Sections Stock Incentive Plan - The stock incentive plan involves granting a total of 704,000 restricted shares, accounting for 0.79% of the company's total share capital of 89.6 million shares, to 54 individuals including senior management and key technical personnel [3]. Financial Performance and Forecast - The company expects revenue for 2024 to decline by 21% to 884 million yuan, with a net profit forecast of 161 million yuan, a decrease of 46% [4]. - Revenue growth is projected to rebound to 30% in 2025 and 28% in 2026, with net profit growth of 28% and 31% respectively [4][5]. - The earnings per share (EPS) is expected to be 1.80 yuan in 2024, increasing to 2.31 yuan in 2025 and 3.03 yuan in 2026 [5]. Market Position and Strategy - The company is positioned as a leading domestic manufacturer of ventilators, with a strong market share in the U.S. and plans for global expansion [4]. - The international business accounted for 60.55% of revenue in the first three quarters of 2024, indicating a growing reliance on overseas markets [4].

转自：北京日报客户端 作为中关村论坛的重要组成部分，2025中关村国际技术交易大会近日召开。在活动现场，《百项新技术 新产品榜单》《百项国际技术交易创新项目榜单》双榜齐发。 "两榜单"进一步聚焦新一代信息技术、新材料、智能装备、医药健康等高精尖产业领域，面向全球40多 个国家和地区征集1472项创新项目，最终评议产生200项新成果，助推前沿科研成果走下"书架"，走 上"货架"，加速产业化落地，展现全球技术交易生态澎湃活力。 硬核科技项目向全球推介 中关村国际技术交易大会正逐渐成为政策首发、成果首秀的国际舞台，本次大会开幕式上持续发布《百 项新技术新产品榜单》《百项国际技术交易创新项目榜单》。今年"两榜单"较往年呈现质量更高、引领 更强等特点。 其中，《百项新技术新产品榜单》旨在展示一批前沿技术产品，推动科研成果走向市场，转化为现实生 产力；《百项国际技术交易创新项目榜单》重点聚焦"国际技术交易合作"，面向全球遴选可转化、可转 移、可交易、可落地的高质量创新技术项目。 比博斯特（上海）汽车电子有限公司凭借其集成式线控制动系统BIBC （One-Box）这一创新成果，成 功跻身两大权威榜单。该项目技术负责人说，从 ...

// 市场要闻 // 国有大行重磅官宣。 3月30日下午，中国银行、中国建设银行、交通银行发布公告称，董事会通过 了向特定对象发行A股股票条件的议案。其中，建设银行拟引入财政部战略投资，募资总额不超过 人民币1050亿元。交通银行拟定增募资不超过1200亿元，发行对象为财政部、中国烟草和双维投 资，其中财政部拟认购金额为1124.2亿元。募资均用于补充核心一级资本。中国银行拟向特定对象 发行A股股票，募集资金总额不超过1650亿元。 社保基金重仓这些股票。 随着上市公司年报密集披露，作为长线资金代表的社保基金 2024 年末重 仓股及持股变动情况浮出水面。 Wind数据显示，截至3月28日，已有938家上市公司披露了2024年年报，其中有133家上市公司（包含2 家未披露年报但已披露2024年末十大流通股东上市公司）的前十大流通股东中出现了社保基金的身影。 2024年四季度，社保基金新进29只个股的前十大流通股东序列，同时对40只个股的持股数量增加。 自由现金流 ETF 近期成为基金行业的一大焦点。 在挖掘基金重仓股上只看净利润不看现金流的策 略，使得许多基金经理在过去三年间积累了大量有关忽视自由现金流的"苦 ...

Group 1 - The core message emphasizes that China remains an ideal and secure investment destination for foreign enterprises, highlighting the mutual benefits of foreign investment in China [2][3]. - As of now, foreign investment in China spans 20 industry categories and 115 subcategories, with a total of 1.24 million enterprises established and an investment amount nearing 3 trillion USD [3]. - Foreign enterprises contribute significantly to China's economy, accounting for one-third of imports and exports, one-fourth of industrial added value, and one-seventh of tax revenue, while creating over 30 million jobs [4]. Group 2 - China's economic resilience provides a stable anchor for investors, with key economic indicators showing growth: industrial added value increased by 5.9%, service production index by 5.6%, fixed asset investment by 4.1%, and retail sales by 4.0% in the first two months of the year [5]. - The consumer confidence index has been rising for three consecutive months, supported by a series of policies aimed at boosting consumption [5]. - Infrastructure investment grew by 5.6% and high-tech industry investment by 9.7%, indicating strong investment momentum [5]. Group 3 - China has a vast consumer market with over 1.4 billion people, including more than 400 million in the middle-income group, driving diverse demands in quality consumption and emerging technology industries [6]. - Major international events like the Boao Forum and the China International Import Expo serve as platforms for foreign enterprises to seize opportunities in the Chinese market [6][7]. Group 4 - The establishment of 22 free trade zones and the reduction of the foreign investment negative list from 190 to 29 items demonstrate China's commitment to opening up its economy [10]. - The "2025 Action Plan for Stabilizing Foreign Investment" outlines 20 specific measures to enhance investment promotion and service support, marking a significant policy initiative aimed at attracting foreign investment [10][11]. - Recent investments by foreign companies in China, such as Boston Scientific and Siemens, reflect a strong commitment to expanding operations in the country [12].